Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.46 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11108872 | 0.90 | KMT2A (0.51) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL2046121 | 0.84 | KMT2A (0.49) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL10224215 | 0.82 | L3MBTL1 (0.58) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL31692849 | 0.82 | L3MBTL1 (0.36) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL254754 | 0.81 | ALDH1A1 (0.54) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL18309270 | 0.81 | L3MBTL1 (0.60) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL10224229 | 0.81 | L3MBTL1 (0.65) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL8974440 | 0.80 | KCNN2 (0.40) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL19445344 | 0.80 | PPARG (0.42) | KMT2AMEN1L3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL30741241 | 0.80 | CA12 (0.48) | L3MBTL1CYP1A2LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150203489-A1 | TRISUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES, METHODS FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | UNIVERSITE D'ORLEANS (FR) | 2015-07-23 | — | — | US | disclosed |
| EP-1724013-B1 | ASYMMETRIC REACTION CATALYST AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS WITH THE SAME | JAPAN SCIENCE & TECH AGENCY (JP) | 2015-01-28 | — | — | EP | disclosed |
| US-7910762-B2 | mixing a pentavalent niobium compound and a tetraol having an optically active binapthol; catalysts for the following asymmetric reactions: Mannich, epoxide ring opening, allylation, cyanation, and alkylation; reacting silicon enolate with imine to form beta-aminocarbonyl compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-03-22 | — | — | US | disclosed |
| US-7667078-B2 | Asymmetric reaction catalyst and method for preparing optically active compound using the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20100029968-A1 | ASYMMETRIC REACTION CATALYST AND METHOD FOR PREPARING OPTICALLY ACTIVE COMPOUND USING THE SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-02-04 | — | — | US | disclosed |
| CN-101189248-A | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2008-05-28 | — | — | CN | disclosed |
| US-20070265472-A1 | Asymmetric Reaction Catalyst and Method for Preparing Optically Active Compound Using the Same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1724013-A1 | ASYMMETRIC REACTION CATALYST AND PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS WITH THE SAME | Japan Science and Technology Agency (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203489-A1 | TRISUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES, METHODS FOR PREPARING SAME AND THERAPEUTIC USES THEREOF | DPYD, TYMP, RRM2B | KMT2A 2312/4885MEN1 3121/4885L3MBTL1 3892/4885 |
| US-20100029968-A1 | ASYMMETRIC REACTION CATALYST AND METHOD FOR PREPARING OPTICALLY ACTIVE COMPOUND USING THE SAME | SQLE, DNTT, TDO2 | KMT2A 1430/4885MEN1 1520/4885L3MBTL1 3698/4885 |
| US-20070265472-A1 | Asymmetric Reaction Catalyst and Method for Preparing Optically Active Compound Using the Same | SQLE, TDO2, DNTT | KMT2A 1220/4885MEN1 665/4885L3MBTL1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.